26 September 2011
Sareum Holdings plc
(“Sareum” or “the Company”)
Final Results
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce its final results for the year ended 30 June 2011.
Operational Highlights
Financial Highlights
Tim Mitchell, Chief Executive Officer of the Company, said: “The announcement of two successful in-vivo efficacy studies, and the selection of a preclinical development candidate, bring Sareum closer to the commercialisation of drug candidates from our in-house development pipeline. We are currently actively seeking to license these programmes in order to allow us to drive forward other programmes that have been generated from our SKIL® platform.
The placings during the course of the year, which raised a total of £950,000, have provided us with sufficient working capital for the foreseeable future to continue the current level of development of our in-house programmes.”
Enquiries:
Sareum Holdings plc |
|
Tim Mitchell |
01223 497 700 |
Merchant Securities Limited (Nomad) |
|
Simon Clements |
020 7628 2200 |
Hybridan LLP (Broker) |
|
Claire Noyce |
020 7947 4350 |
The Communications Portfolio (Media enquiries) Ariane Comstive / Caolan Mahon ariane.comstive@communications-portfolio.co.uk |
+44 (0) 20 7536 2028 / 2029 |
Annual Results 2011 available as PDF document:Annual Results 2011